医保招标采购中资金增值对基本药物供应链收益变化的影响

Research on the Influence of the Capital Appreciation on Changement of Essential Drug Supply Chain Profits Based on the Bidding and Procurement by Medical Insurance

医保招标采购拥有逐级支付和并行支付两种不同的支付流程。在一次结算周期内,以幂函数衡量基本药物供需关系,结合零差率销售特征,考虑资金增值作用,构建了两种支付流程的基本药物供应链收益及差值函数,分析了资金收益率和结算时间的单调性质,得出了收益提升的实现条件。数值检验表明:若不考虑资金增值,则两者收益一致;若考虑资金增值,则两者收益发生变化,且资金收益率越高,并行支付流程的改进效果越明显;医保结算时间是影响基本药物供应链运作的关键要素;在维持当前基本药物价格体系的情况下,并行支付流程更有可能创造更多价值。

The bidding and procurement by medical insurance has two different kinds of payment process, namely step by step payment and parallel payment. In their one settlement cycle,the supply-demand relationship of essential drugs is described by power function. Following the zero-profit characteristic of essential drugs, this paper considers the capital appreciation, constructs the profit model of essential drugs supply chain in above two payment processes, analyses the monotonicity of D-value profit function about capital return and settlement time, obtains the realization conditions of improving the essential drugs supply chain profit. The numerical study shows that if take no account of the capital appreciation, the profit is not changed. Whereas, the profit changement is obvious if take account of the capital appreciation, and the higher the capital return rate grow, the more obvious improvement the parallel payment has. In addition, the settlement time of medical insurance is a key factor affects the essential drugs supply chain operation, and the parallel payment process could create more value more likely if that the price system of essential drugs is not changed.